Head-to-head evidence
Empagliflozin vs Rongliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT01131676 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).
Next expected readout: November 2026 · NCT06229678 (registry estimate)
Rongliflozin
Developed by Sunshine Lake Pharma
NCT05427682 · Phase 1 · completed
A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Rongliflozin's landscape